TORONTO, ON, CANADA (October 23, 2017) - Cyclica Inc. is pleased to announce that Issi Rozen has joined its Scientific Advisory Board.
Issi is the Chief Business Officer at the Broad Institute of MIT and Harvard, where he is responsible for partnering with the life sciences industry and venture investors, and developing innovative scientific and business collaborations. He is also responsible for initiating and establishing new ventures around novel research projects and for licensing the institute’s intellectual property portfolio. He joined the Broad Institute in 2011 after a career in the biotech industry. Before joining the Broad Institute, Rozen led corporate development at Resolvyx, a venture-backed biotech start-up. Prior to that, he headed the business analysis group at EMD Serono where he evaluated in-licensing and M&A opportunities and was responsible for commercial analytics and forecasting. He is also a co-founder of a number of Boston-based biotech start-ups, and over the course of his career he has structured, negotiated, and closed transactions with over $500M in upfront payments/research funding and over $5B in milestones, and participated in raising over $150M in seed and series A funding. Issi is also an accomplished jazz guitarist. He earned his M.B.A. at MIT’s Sloan School of Management.
Naheed Kurji, Cyclica’s President and CEO, had this to say, “Issi brings to Cyclica a unique combination of entrepreneurial wisdom, pharmaceutical expertise, and insights on strategic partnering to the industry. His skillsets and experience complement a well-rounded group of advisors who work closely with Cyclica’s management team to guide our ongoing scientific and business endeavours. We are lucky to have Issi on the team, and we look forward to a productive relationship going forward.”
Issi Rozen added, “I’ve become familiar with Cyclica over the past year when they entered the Cambridge marketplace. I’ve enjoyed watching the company grow, and believe in the team, their technology, and their focused strategy to revolutionize the drug discovery value chain by applying a unique computational approach.”
— 30 —
Cyclica Inc. has developed, validated, patented and commercialized Ligand Express™, a cloud-based platform that screens small-molecule drugs against repositories of structurally-characterized proteins or ‘proteomes’ to determine polypharmacological profiles. Accordingly, Ligand Express™ identifies significant protein targets using an innovative structure-based and drug-centric technology, leverages artificial intelligence to determine the drug’s effect on these targets, and visualizes the predicted drug-protein interactome using bioinformatics and systems biology. The platform provides a unique panoramic view of a small-molecule, by identifying on- and off-target interactions that may be expected, as well as those that are unanticipated. By understanding how a small-molecule drug will interact with all proteins in the body, Ligand Express™ augments scientific investigation by elucidating mechanism of action, prioritizing lead candidates, understanding side effects, as well as determining new uses for existing drugs. For more information please visit: www.cyclicarx.com